These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

206 related items for PubMed ID: 6607956

  • 1. The systemic administration of purified interleukin 2 enhances the ability of sensitized murine lymphocytes to cure a disseminated syngeneic lymphoma.
    Donohue JH, Rosenstein M, Chang AE, Lotze MT, Robb RJ, Rosenberg SA.
    J Immunol; 1984 Apr; 132(4):2123-8. PubMed ID: 6607956
    [Abstract] [Full Text] [Related]

  • 2. In vivo administration of purified Jurkat-derived interleukin 2 in mice.
    Donohue JH, Lotze MT, Robb RJ, Rosenstein M, Braziel RM, Jaffe ES, Rosenberg SA.
    Cancer Res; 1984 Apr; 44(4):1380-6. PubMed ID: 6608405
    [Abstract] [Full Text] [Related]

  • 3. Immunotherapy of cancer by systemic administration of lymphoid cells plus interleukin-2.
    Rosenberg SA.
    J Biol Response Mod; 1984 Oct; 3(5):501-11. PubMed ID: 6389777
    [Abstract] [Full Text] [Related]

  • 4. Monoclonal antibody therapy of murine lymphoma: enhanced efficacy by concurrent administration of interleukin 2 or lymphokine-activated killer cells.
    Schultz KR, Klarnet JP, Peace DJ, Cheever MA, Badger CC, Bernstein ID, Greenberg PD.
    Cancer Res; 1990 Sep 01; 50(17):5421-5. PubMed ID: 2386946
    [Abstract] [Full Text] [Related]

  • 5. Eradication of a disseminated syngeneic mouse lymphoma by systemic adoptive transfer of immune lymphocytes and its dependence upon a host component(s).
    Mulé JJ, Rosenstein M, Shu S, Rosenberg SA.
    Cancer Res; 1985 Feb 01; 45(2):526-31. PubMed ID: 3881168
    [Abstract] [Full Text] [Related]

  • 6. Recombinant interleukin 2 stimulates in vivo proliferation of adoptively transferred lymphokine-activated killer (LAK) cells.
    Ettinghausen SE, Lipford EH, Mulé JJ, Rosenberg SA.
    J Immunol; 1985 Nov 01; 135(5):3623-35. PubMed ID: 3900213
    [Abstract] [Full Text] [Related]

  • 7. Adoptive immunotherapy of microscopic and advanced visceral metastases with in vitro sensitized lymphoid cells from mice bearing progressive tumors.
    Chou T, Bertera S, Chang AE, Shu S.
    J Immunol; 1988 Sep 01; 141(5):1775-81. PubMed ID: 3261761
    [Abstract] [Full Text] [Related]

  • 8. In vitro sensitization and expansion with viable tumor cells and interleukin 2 in the generation of specific therapeutic effector cells.
    Shu S, Chou T, Rosenberg SA.
    J Immunol; 1986 May 15; 136(10):3891-8. PubMed ID: 3486223
    [Abstract] [Full Text] [Related]

  • 9. Immunotherapy of murine and human tumors in mice with lymphokines and interleukin-2-propagated lymphocytes.
    Kedar E, Chriqui-Zeira E, Kyriazis AP.
    J Biol Response Mod; 1984 Oct 15; 3(5):517-26. PubMed ID: 6334139
    [Abstract] [Full Text] [Related]

  • 10. Generation of long-term T-lymphoid cell lines with specific cytotoxic reactivity for a syngeneic murine lymphoma.
    Eberlein TJ, Rosenstein M, Spiess PJ, Rosenberg SA.
    J Natl Cancer Inst; 1982 Jul 15; 69(1):109-16. PubMed ID: 6980314
    [Abstract] [Full Text] [Related]

  • 11. Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2.
    Lafreniere R, Rosenberg SA.
    Cancer Res; 1985 Aug 15; 45(8):3735-41. PubMed ID: 3893689
    [Abstract] [Full Text] [Related]

  • 12. Immunotherapy of murine sarcomas using lymphokine activated killer cells: optimization of the schedule and route of administration of recombinant interleukin-2.
    Ettinghausen SE, Rosenberg SA.
    Cancer Res; 1986 Jun 15; 46(6):2784-92. PubMed ID: 3486038
    [Abstract] [Full Text] [Related]

  • 13. Eradication of disseminated murine leukemia by treatment with high-dose interleukin 2.
    Thompson JA, Peace DJ, Klarnet JP, Kern DE, Greenberg PD, Cheever MA.
    J Immunol; 1986 Dec 01; 137(11):3675-80. PubMed ID: 3491145
    [Abstract] [Full Text] [Related]

  • 14. Adoptive immunotherapy of a syngeneic murine leukemia with a tumor-specific cytotoxic T cell clone and recombinant human interleukin 2: correlation with clonal IL 2 receptor expression.
    Matis LA, Shu S, Groves ES, Zinn S, Chou T, Kruisbeek AM, Rosenstein M, Rosenberg SA.
    J Immunol; 1986 May 01; 136(9):3496-501. PubMed ID: 2420893
    [Abstract] [Full Text] [Related]

  • 15. Host CD4+ T lymphocytes are required for the synergistic action of interferon-alpha/beta and adoptively transferred immune cells in the inhibition of visceral ESb metastases.
    Kaido TJ, Maury C, Gresser I.
    Cancer Res; 1995 Dec 15; 55(24):6133-9. PubMed ID: 8521404
    [Abstract] [Full Text] [Related]

  • 16. Therapy of advanced solid tumors in mice using chemotherapy in combination with interleukin-2 with and without lymphokine-activated killer cells.
    Kedar E, Ben-Aziz R, Shiloni E.
    Isr J Med Sci; 1988 Dec 15; 24(9-10):494-504. PubMed ID: 3264551
    [Abstract] [Full Text] [Related]

  • 17. Vaccinia colon oncolysate immunotherapy for murine hepatic metastases can be modulated with low-dose interleukin-2. Third place winner: Conrad Jobst Award.
    Barnavon Y, Iwaki H, Bash JA, Wallack MK.
    Am Surg; 1988 Dec 15; 54(12):696-701. PubMed ID: 3264127
    [Abstract] [Full Text] [Related]

  • 18. Local conditions in the host influence immunotherapy with interleukin-2 and LAK cells.
    Steller EP, Ottow RT, Eggermont AM, Marquet RL, Sugarbaker PH.
    Cancer Detect Prev; 1988 Dec 15; 12(1-6):81-90. PubMed ID: 3263202
    [Abstract] [Full Text] [Related]

  • 19. Adoptive immunotherapy of established syngeneic solid tumors: role of T lymphoid subpopulations.
    Rosenstein M, Eberlein TJ, Rosenberg SA.
    J Immunol; 1984 Apr 15; 132(4):2117-22. PubMed ID: 6607955
    [Abstract] [Full Text] [Related]

  • 20. Anti-tumor effects of local irradiation in combination with peritumoral administration of low doses of recombinant interleukin-2 (rIL-2).
    Jürgenliemk-Schulz IM, Renes IB, Rutgers DH, Everse LA, Bernsen MR, Den Otter W, Battermann JJ.
    Radiat Oncol Investig; 1997 Apr 15; 5(2):54-61. PubMed ID: 9303058
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.